Eisai Formally Submits BLA for Subcutaneous Autoinjector of Lecanemab

A subgroup analysis of the phase 3 Clarity AD open-label extension study showed a 14% increased amyloid plaque removal with subcutaneous lecanemab vs intravenous administration, the administration for which it was FDA-approved for.:

Source: Neurology Read More